Search hospitals > Texas > Houston
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
Claim this profileHouston, Texas 77030
Global Leader in Cancer
Global Leader in Tumors
Conducts research for Recurrence
Conducts research for Leukemia
Conducts research for Lymphoma
295 reported clinical trials
47 medical researchers
Summary
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center is a medical facility located in Houston, Texas. This center is recognized for care of Cancer, Tumors, Recurrence, Leukemia, Lymphoma and other specialties. Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center is involved with conducting 295 clinical trials across 497 conditions. There are 47 research doctors associated with this hospital, such as Jennifer Foster, MD, Patricia Baxter, MD, Mothaffar Rimawi, MD, and Ahmed Elkhanany.Area of expertise
1Cancer
Global LeaderStage IV
Stage I
Stage II
2Tumors
Global LeaderStage IV
Stage I
Stage II
Top PIs
Jennifer Foster, MDBaylor College of Medicine/Dan L Duncan Comprehensive Cancer Center2 years of reported clinical research
Expert in Tumors
Expert in Neuroblastoma
33 reported clinical trials
49 drugs studied
Patricia Baxter, MDTexas Children's Hospital2 years of reported clinical research
Expert in Brain Tumor
Expert in Diffuse Intrinsic Pontine Glioma
32 reported clinical trials
40 drugs studied
Mothaffar Rimawi, MDBaylor College of Medicine5 years of reported clinical research
Studies Breast Cancer
Studies Cancer
10 reported clinical trials
22 drugs studied
Ahmed ElkhananyUniversity of Alabama at Birmingham1 year of reported clinical research
Studies Breast Cancer
Studies Cancer
10 reported clinical trials
24 drugs studied
Clinical Trials running at Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
Breast Cancer
Cancer
Osteosarcoma
Bladder Cancer
Non-Small Cell Lung Cancer
Brain Tumor
Lung Cancer
Squamous Cell Carcinoma
Non-Hodgkin's Lymphoma
Lymphoma
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Omitting Radiation Therapy
for Breast Cancer
The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.
Recruiting2 awards Phase 319 criteria
Support Program
for Breast Cancer
This phase III trial compares an additional support program (text message reminders and/or telephone-based counseling) with usual care in making sure breast cancer patients take their endocrine therapy medication as prescribed (medication adherence). Medication adherence is how well patients take the medication as prescribed by their doctors, and good medical adherence is when patients take medications correctly. Poor medication adherence has been shown to be a serious barrier to effective treatment for hormone receptor positive breast cancer patients. Adding text message reminders and/or telephone-based counseling to usual care may increase the number of days that patients take their endocrine therapy medication as prescribed.
Recruiting2 awards Phase 34 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center?
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center is a medical facility located in Houston, Texas. This center is recognized for care of Cancer, Tumors, Recurrence, Leukemia, Lymphoma and other specialties. Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center is involved with conducting 295 clinical trials across 497 conditions. There are 47 research doctors associated with this hospital, such as Jennifer Foster, MD, Patricia Baxter, MD, Mothaffar Rimawi, MD, and Ahmed Elkhanany.